Drugs / Recombinant Granulocyte Colony-Stimulating Factor
Recombinant Granulocyte Colony-Stimulating Factor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02739295 | Jul 2016 → Mar 2023 | Stevens-Johnson syndrome | University of Liege | Completed | No outcome recorded |
| Comparator or background therapy10 trials | ||||||
| Phase 1 | NCT07020533 Background | May 2026 → May 2028 expected | Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, leukemia, myeloid, accelerated-phase +3 | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04196010 Background | May 2020 → Oct 2021 | acute myeloid leukemia | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT04797767 Background | Feb 2022 → Dec 2027 expected | acute biphenotypic leukemia, myeloid sarcoma | University of Washington | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03670966 Background | Jul 2019 → Jan 2028 expected | acute lymphoblastic leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome with excess blasts | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07605416 Background | Jul 2026 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07046078 Background | Sep 2025 → Jun 2027 expected | acute leukemia of ambiguous lineage, chronic myelomonocytic leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04871607 Background | Nov 2021 → Oct 2029 expected | Hodgkins lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04370301 Background | Feb 2021 → Apr 2027 expected | myelofibrosis, primary myelofibrosis | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04195945 Background | May 2020 → Jun 2025 | acute myeloid leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 4 | NCT07101445 Background | Sep 2025 → Dec 2026 expected | plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant granulocyte - colony stimulating factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02739295 ↗ |
| Known as | G-CSF | “An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.” NCT02739295 ↗ |
| Known as | Neupogen | “An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.” NCT02739295 ↗ |
| Known as | rhG-CSF | “rhG-CSF” NCT03670966 ↗ |
| Modality | Protein / enzyme biologic | “recombinant granulocyte - colony stimulating factor” NCT02739295 ↗ |
| Route | Intravenous | “An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.” NCT02739295 ↗ |